

DDD Notice No. 19036 posted February 20, 2019 ODB FORMULARY – EDITION NO. 43, Summary of Changes – February 2019

We are pleased to provide you with the Summary of Changes – February 2019 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective **February 28, 2019**. The Edition No. 43 document will be posted on the Ministry's website http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx by February 28, 2019.

The information in this Summary of Changes – February 2019 is based on the decisions made by the Executive Officer, taking into consideration recommendations from the Ministry's expert advisory committee, the Committee to Evaluate Drugs (CED).

Listing Changes

- 1 single source drug molecule (1 DIN)
- 3 multiple source drug molecules (3 DINs)
- 2 Off-Formulary Interchangeable (OFI) drug molecules (4 DINs)
- 1 drug molecule (1 DIN) funded through the Exceptional Access Program

Single Source Product

Maviret (glecaprevir/pibrentasvir) 100mg & 40mg Tab (ABV)

For the treatment of Hepatitis C, with Limited Use (LU) Codes 550 (8 weeks), 551 (12 weeks) and 552 (16 weeks). For details, please see the February 2019 Summary of Changes document posted at http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx.

Multiple Source Products

Jamp-Tenofovir 300mg Tab	JPC
Mint-Hydrochlorothiazide 25mg Tab	MIN
Sandoz Morphine SR 100mg SR Tab	SDZ

Exceptional Access Program (EAP) Product

Quinsair (levofloxacin hemihydrate) 240mg/2.4mL Inh Sol-2.4mL Amp (HPI) – Effective Date: February 4, 2019

For the treatment of *Pseudomonas aeruginosa* infection in patients with cystic fibrosis according to clinical criteria.

The reimbursement criteria for the above product will be included on the list of Frequently Requested Drugs, which can be found on the Ministry's website: http://www.health.gov.on.ca/en/pro/programs/drugs/pdf/frequently_requested_drugs.pdf

The Ministry has posted a new file with the listing changes for download and review (Edition No. 43, Summary of Changes – February 2019). It is accessible from the Ministry's website: http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx.

In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the ministry's website: <https://www.formulary.health.gov.on.ca/formulary/> - The e-Formulary will be updated on the effective date – February 28, 2019.

We appreciate your continued cooperation in making these benefit adjustments.